TY - JOUR
T1 - European advances in digital rheumatology
T2 - explainable insights and personalized digital health tools for psoriatic arthritis
AU - iPROLEPSIS consortium
AU - Hadjileontiadis, Leontios J.
AU - Charisis, Vasileios
AU - Hadjidimitriou, Stelios
AU - Dias, Sofia B.
AU - Apostolidis, George
AU - Dimaridis, Giannis
AU - Kitsas, Ilias
AU - Karlas, Angelos
AU - Fasoula, Nikolina Alexia
AU - Levi-Schaffer, Francesca
AU - Silva, Hugo
AU - Dimitroulas, Theodoros
AU - Rodrigues, Ana Maria
AU - Coates, Laura C.
AU - Luime, Jolanda
AU - Tchetverikov, Ilja
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025/6
Y1 - 2025/6
N2 - The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, the PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients' interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem.
AB - The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, the PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients' interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem.
KW - Digital rheumatology
KW - Digital therapeutics
KW - Explainable AI models
KW - iPROLEPSIS European research initiative
KW - Novel digital biomarkers
KW - Psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=105005085768&partnerID=8YFLogxK
U2 - 10.1016/j.eclinm.2025.103243
DO - 10.1016/j.eclinm.2025.103243
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:105005085768
SN - 2589-5370
VL - 84
JO - eClinicalMedicine
JF - eClinicalMedicine
M1 - 103243
ER -